A pilot study comparing daily teriparatide with monthly cycles of teriparatide and raloxifene.

Goel H, Libber J, Borchardt G, Krueger D, Binkley N

Archives of osteoporosis15 Apr 2021Cited by 3 (Europe PMC)

PMID33856570DOI10.1007/s11657-021-00933-6PepBankPUB-33856570

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar DXA BMD similarly.
In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar bone density similarly by DXA.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD by DXA
Study
n = 26
Comparator
Daily teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
DXA BMD increase
4.8%
daily teriparatide
DXA BMD increase
5.2%
cyclic teriparatide/raloxifene
Source sentences
Summary
LS-BMD increased (p<0.001) with TPD or TPD/RLX as measured by DXA (4.8%/5.2%), QCT (13%/9.4%), or HU (15.6%/10.2%) with no between-group difference.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6-month pilot study in osteoporotic postmenopausal women evaluated cyclic TPD/RLX compared to daily subcutaneous TPD with the concept of optimizing bone formation.
Summary · context
Postmenopausal osteoporotic women (n=26) were randomized to open-label TPD 20 daily or alternating monthly cycles of TPD followed by monthly RLX 60 mg daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3385657001
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar QCT BMD similarly.
In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar bone density similarly by QCT.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD by QCT
Study
n = 26
Comparator
Daily teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
QCT BMD increase
13%
daily teriparatide
QCT BMD increase
9.4%
cyclic teriparatide/raloxifene
Source sentences
Summary
LS-BMD increased (p<0.001) with TPD or TPD/RLX as measured by DXA (4.8%/5.2%), QCT (13%/9.4%), or HU (15.6%/10.2%) with no between-group difference.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6-month pilot study in osteoporotic postmenopausal women evaluated cyclic TPD/RLX compared to daily subcutaneous TPD with the concept of optimizing bone formation.
Summary · context
Postmenopausal osteoporotic women (n=26) were randomized to open-label TPD 20 daily or alternating monthly cycles of TPD followed by monthly RLX 60 mg daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3385657002
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar Hounsfield units similarly.
In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene and daily teriparatide increased lumbar scan density similarly.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine Hounsfield units
Study
n = 26
Comparator
Daily teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
HU increase
15.6%
daily teriparatide
HU increase
10.2%
cyclic teriparatide/raloxifene
Source sentences
Summary
LS-BMD increased (p<0.001) with TPD or TPD/RLX as measured by DXA (4.8%/5.2%), QCT (13%/9.4%), or HU (15.6%/10.2%) with no between-group difference.
2 context sentences(design, population, supporting numbers)
Summary · context
This 6-month pilot study in osteoporotic postmenopausal women evaluated cyclic TPD/RLX compared to daily subcutaneous TPD with the concept of optimizing bone formation.
Summary · context
Postmenopausal osteoporotic women (n=26) were randomized to open-label TPD 20 daily or alternating monthly cycles of TPD followed by monthly RLX 60 mg daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3385657003
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene improved total proximal femur BMD more than daily teriparatide.
In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene improved proximal femur bone density more than daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal proximal femur BMD
Study
n = 26
Comparator
Daily teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Between-group BMD difference
1.5%
cyclic versus daily
Source sentences
Summary
TPD/RLX produced beneficial between-group differences in total proximal femur BMD (1.5%, p<0.05) and cortical thickness (1.6%, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This 6-month pilot study in osteoporotic postmenopausal women evaluated cyclic TPD/RLX compared to daily subcutaneous TPD with the concept of optimizing bone formation.
Summary · context
Postmenopausal osteoporotic women (n=26) were randomized to open-label TPD 20 daily or alternating monthly cycles of TPD followed by monthly RLX 60 mg daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3385657004
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene improved cortical thickness more than daily teriparatide.
In plain wordsIn postmenopausal women with osteoporosis, cyclic teriparatide/raloxifene improved outer bone thickness more than daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical thickness
Study
n = 26
Comparator
Daily teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Between-group cortical thickness difference
1.6%
cyclic versus daily
Source sentences
Summary
TPD/RLX produced beneficial between-group differences in total proximal femur BMD (1.5%, p<0.05) and cortical thickness (1.6%, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This 6-month pilot study in osteoporotic postmenopausal women evaluated cyclic TPD/RLX compared to daily subcutaneous TPD with the concept of optimizing bone formation.
Summary · context
Postmenopausal osteoporotic women (n=26) were randomized to open-label TPD 20 daily or alternating monthly cycles of TPD followed by monthly RLX 60 mg daily.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3385657005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.